For medicines intended for chronic use, the number of patients studied before regulatory approval in the European Union (EU) is insufficient to properly evaluate safety and long-term efficacy, and this points to a need for new EU legislation, say researchers writing in this week's PLOS Medicine.
- Published
- 12 hours ago
- From
-
Pharma Times
We need to design prevention trials that ask, “Is this test product better than nothing?” rather than, “Is this test product better than the best available prevention combination we have?”
- Published
- 15 March 2013
- From
-
Poz
The National Institutes of Health (NIH) should reduce its use of chimpanzees for medical research, according to an NIH-commissioned working group.
- Published
- 06 February 2013
- From
- Poz magazine news
A potential breakthrough in the quest to prevent HIV and AIDS has collided with sensitivities about testing expensive drugs in poor parts of the world.
- Published
- 17 January 2013
- From
-
Nature.com
Drugs and medical devices tend to appear more beneficial in scientific papers if they were manufactured by the company that sponsored the study, showing that who pays for the clinical trial has a direct impact on the reported outcome, according to a new analysis by researchers at UCSF and the Cochrane Collaboration.
- Published
- 20 December 2012
- From
-
University of California press release
A proposed trial of low-dose
stavudine (also known as d4T) sparked a heated debate between South African researchers and activists at the opening of the first
Southern
- Published
- 11 December 2012
- By
- Lesley Odendal
Arguably the most prestigious medical journal in the world, the New England Journal of Medicine regularly features articles over which pharmaceutical companies and their employees can exert significant influence.
- Published
- 26 November 2012
- From
-
Washington Post
Two years ago US authorities arrested and charged Yves Benhamou, a French doctor, with insider trading linked to passing on his confidential knowledge of clinical trials of Albuferon, a hepatitis drug. That was one of a growing series of criminal investigations in the healthcare sector, many of which start with connections via “expert networks”, essentially companies which convene meetings, for a fee, between investors and medical experts.
- Published
- 24 November 2012
- From
-
Financial Times
Several studies, or updates of studies, comparing newer against
older drug regimens were presented at the Eleventh International Congress on Drug Therapy
in HIV Infection last week.
- Published
- 20 November 2012
- By
- Gus Cairns
French HIV prevention activist group The Warning has issued a press release saying that the placebo arm of the French IPERGAY randomised controlled study of intermittent PrEP should be dropped.
This is in response to a 31 October press release by the French National HIV Research Agency, ANRS, that said it should continue - see http://public.adequatesystems.com/pub/link/203893/034296629555571351674647159-anrs.fr.html .
The Warning's position does not reflect the position of other French community organisations, which take positions from support of the IPERGAY trial as it is, to demanding PrEP be made available alongside the trial, to total rejection of it.
See http://www.ipergay.fr/Les-avis-des-comites-sur-la-poursuite-de-l-essai-Ipergay_a91.html for a sumary of community reports to the trial co-ordinators (in French).
- Published
- 09 November 2012
- From
-
The Warning
Get set for HIV treatmentA tool to help you decide whether you are ready to start taking HIV treatment.
HIV, GPs & other primary careThis booklet explains the services GPs offer, how this fits with HIV specialist care, and how to make the most of primary care services.
Treatment as prevention – free webinar 20 March 2013As
part of its European HIV prevention work, NAM is collaborating...
Microbicides research – free webinar 22 February 2013As
part of its European HIV prevention work, NAM is collaborating...
HIV treatment update – Winter 2013 21 February 2013The new edition of HIV treatment update (HTU) is on...